共 50 条
- [3] REVERSIBILITY OF RENAL FAILURE IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS: A SINGLE CENTRE EXPERIENCE [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 593 - 593
- [5] Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (04): : 302 - 306
- [6] Superior myeloma response with bortezomib-based regimen in multiple myeloma patients with renal impairment [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03): : 6200 - 6209
- [7] BORTEZOMIB-BASED REGIMENS AS INDUCTION AND MAINTENANCE TREATMENT IN MULTIPLE MYELOMA (MM) PATIENTS NOT ELIGIBLE FOR AGGRESSIVE THERAPY [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 544 - 544
- [10] Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens [J]. International Journal of Hematology, 2013, 97 : 382 - 387